Human Melanoma Antigens Recognized by T Lymphocytes

この論文にアクセスする

この論文をさがす

著者

    • 河上 裕 KAWAKAMI Yutaka
    • Surgery Branch, National Cancer Institute, National Institutes of Health Surgery Branch, National Cancer Institute, National Institutes of Health
    • ROBBINS Paul F
    • Surgery Branch, National Cancer Institute, National Institutes of Health Surgery Branch, National Cancer Institute, National Institutes of Health
    • ROSENBERG Steven A
    • Surgery Branch, National Cancer Institute, National Institutes of Health Surgery Branch, National Cancer Institute, National Institutes of Health

抄録

Human melanoma antigens and their epitopes recognized by T cells have been identified using a variety of methods. These antigens are classified as 1) melanocyte specific melanosomal proteins (MART-1, gp100, tyrosinase and TRP-1), 2) proteins expressed in testis and a variety of cancers (MAGE-1, MAGE-3, BAGE and GAGE), 3) tumor specific mutated proteins (β-catenin, MUM-1 and CDK4), and 4) others (p15). Some of the HLA-A2 binding non-mutated melanoma epitopes contained non-dominant anchor amino acids and have relatively low HLA-A2 binding affinity, suggesting that these epitopes were likely to be subdominant or cryptic self determinants. The significant correlation observed between vitiligo development and IL2 based immunotherapy suggested that autoreactive T cells specific for these self peptides were involved in melanoma regression <i>in vivo</i>. In addition, since adoptive transfer into patients of CTL recognizing these epitopes resulted in tumor regression, these epitopes may be tumor rejection antigens. Melanoma reactive CTL were efficiently induced from PBL of patients by <i>in vitro</i> stimulation with PBMC pulsed with these melanoma epitopes and may be useful in adoptive transfer protocols for the treatment of patients with metastatic melanoma. An immunization trial using the MART-1 and gp100 peptides in conjunction with incomplete Freund's adjuvant is in progress. These identified antigens may be useful for the development of new immunotherapies for the treatment of melanoma patients as well as for understanding the mechanisms of anti-tumor immune responses and autoimmune disorders against melanocytes.

収録刊行物

  • Keio journal of medicine  

    Keio journal of medicine 45(2), 100-108, 1996-06-01 

    The Keio Journal of Medicine

参考文献:  75件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

被引用文献:  1件

被引用文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10021985939
  • NII書誌ID(NCID)
    AA00710216
  • 本文言語コード
    ENG
  • 資料種別
    REV
  • ISSN
    00229717
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ